Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease
A. Olson (Denver, United States of America), T. Maher (London, United Kingdom), M. Salisbury (Ann Arbor, United States of America), V. Acciai (Ingelheim am Rhein, Germany), B. Mounir (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Zouad-Lejour (Ingelheim am Rhein, Germany), C. Wells (Burlington, United States of America), A. Fischer (Denver, United States of America)
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Olson (Denver, United States of America), T. Maher (London, United Kingdom), M. Salisbury (Ann Arbor, United States of America), V. Acciai (Ingelheim am Rhein, Germany), B. Mounir (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Zouad-Lejour (Ingelheim am Rhein, Germany), C. Wells (Burlington, United States of America), A. Fischer (Denver, United States of America). Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease. 3658
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: